United States Biosimilar Market Report 2017

August 2017 | 99 pages | ID: U15E974ECBAEN
QYResearch

Abstracts

In this report, the United States Biosimilar market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:

• The West
• Southwest
• The Middle Atlantic
• New England
• The South
• The Midwest
• with sales (volume), revenue (value), market share and growth rate of Biosimilar in these regions, from 2012 to 2022 (forecast).

United States Biosimilar market competition by top manufacturers/players, with Biosimilar sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including

• Pfizer
• Roche
• Eli Lilly
• Bayer
• Amgen
• Sanofi-Aventis
• Johnson & Johnson
• Novo Nordisk
• Merck

On the basis of product, this report displays the sales volume, revenue, product price, market share and growth rate of each type, primarily split into

• Antibody
• Hormone
• Growth Factors
• Other

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Biosimilar for each application, including

• Tumor
• Diabetes
• Cardiovascular
• Hemophilia
• Other

If you have any special requirements, please let us know and we will offer you the report as you want.

Contents

United States Biosimilar Market Report 2017

1 BIOSIMILAR OVERVIEW

1.1 Product Overview and Scope of Biosimilar
1.2 Classification of Biosimilar by Product Category
  1.2.1 United States Biosimilar Market Size (Sales Volume) Comparison by Type (2012-2022)
  1.2.2 United States Biosimilar Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
  1.2.3 Antibody
  1.2.4 Hormone
  1.2.5 Growth Factors
  1.2.6 Other
1.3 United States Biosimilar Market by Application/End Users
  1.3.1 United States Biosimilar Market Size (Consumption) and Market Share Comparison by Application (2012-2022)
  1.3.2 Tumor
  1.3.3 Diabetes
  1.3.4 Cardiovascular
  1.3.5 Hemophilia
  1.3.6 Other
1.4 United States Biosimilar Market by Region
  1.4.1 United States Biosimilar Market Size (Value) Comparison by Region (2012-2022)
  1.4.2 The West Biosimilar Status and Prospect (2012-2022)
  1.4.3 Southwest Biosimilar Status and Prospect (2012-2022)
  1.4.4 The Middle Atlantic Biosimilar Status and Prospect (2012-2022)
  1.4.5 New England Biosimilar Status and Prospect (2012-2022)
  1.4.6 The South Biosimilar Status and Prospect (2012-2022)
  1.4.7 The Midwest Biosimilar Status and Prospect (2012-2022)
1.5 United States Market Size (Value and Volume) of Biosimilar (2012-2022)
  1.5.1 United States Biosimilar Sales and Growth Rate (2012-2022)
  1.5.2 United States Biosimilar Revenue and Growth Rate (2012-2022)

2 UNITED STATES BIOSIMILAR MARKET COMPETITION BY PLAYERS/SUPPLIERS

2.1 United States Biosimilar Sales and Market Share of Key Players/Suppliers (2012-2017)
2.2 United States Biosimilar Revenue and Share by Players/Suppliers (2012-2017)
2.3 United States Biosimilar Average Price by Players/Suppliers (2012-2017)
2.4 United States Biosimilar Market Competitive Situation and Trends
  2.4.1 United States Biosimilar Market Concentration Rate
  2.4.2 United States Biosimilar Market Share of Top 3 and Top 5 Players/Suppliers
  2.4.3 Mergers & Acquisitions, Expansion in United States Market
2.5 United States Players/Suppliers Biosimilar Manufacturing Base Distribution, Sales Area, Product Type

3 UNITED STATES BIOSIMILAR SALES (VOLUME) AND REVENUE (VALUE) BY REGION (2012-2017)

3.1 United States Biosimilar Sales and Market Share by Region (2012-2017)
3.2 United States Biosimilar Revenue and Market Share by Region (2012-2017)
3.3 United States Biosimilar Price by Region (2012-2017)

4 UNITED STATES BIOSIMILAR SALES (VOLUME) AND REVENUE (VALUE) BY TYPE (PRODUCT CATEGORY) (2012-2017)

4.1 United States Biosimilar Sales and Market Share by Type (Product Category) (2012-2017)
4.2 United States Biosimilar Revenue and Market Share by Type (2012-2017)
4.3 United States Biosimilar Price by Type (2012-2017)
4.4 United States Biosimilar Sales Growth Rate by Type (2012-2017)

5 UNITED STATES BIOSIMILAR SALES (VOLUME) BY APPLICATION (2012-2017)

5.1 United States Biosimilar Sales and Market Share by Application (2012-2017)
5.2 United States Biosimilar Sales Growth Rate by Application (2012-2017)
5.3 Market Drivers and Opportunities

6 UNITED STATES BIOSIMILAR PLAYERS/SUPPLIERS PROFILES AND SALES DATA

6.1 Pfizer
  6.1.1 Company Basic Information, Manufacturing Base and Competitors
  6.1.2 Biosimilar Product Category, Application and Specification
    6.1.2.1 Product A
    6.1.2.2 Product B
  6.1.3 Pfizer Biosimilar Sales, Revenue, Price and Gross Margin (2012-2017)
  6.1.4 Main Business/Business Overview
6.2 Roche
  6.2.2 Biosimilar Product Category, Application and Specification
    6.2.2.1 Product A
    6.2.2.2 Product B
  6.2.3 Roche Biosimilar Sales, Revenue, Price and Gross Margin (2012-2017)
  6.2.4 Main Business/Business Overview
6.3 Eli Lilly
  6.3.2 Biosimilar Product Category, Application and Specification
    6.3.2.1 Product A
    6.3.2.2 Product B
  6.3.3 Eli Lilly Biosimilar Sales, Revenue, Price and Gross Margin (2012-2017)
  6.3.4 Main Business/Business Overview
6.4 Bayer
  6.4.2 Biosimilar Product Category, Application and Specification
    6.4.2.1 Product A
    6.4.2.2 Product B
  6.4.3 Bayer Biosimilar Sales, Revenue, Price and Gross Margin (2012-2017)
  6.4.4 Main Business/Business Overview
6.5 Amgen
  6.5.2 Biosimilar Product Category, Application and Specification
    6.5.2.1 Product A
    6.5.2.2 Product B
  6.5.3 Amgen Biosimilar Sales, Revenue, Price and Gross Margin (2012-2017)
  6.5.4 Main Business/Business Overview
6.6 Sanofi-Aventis
  6.6.2 Biosimilar Product Category, Application and Specification
    6.6.2.1 Product A
    6.6.2.2 Product B
  6.6.3 Sanofi-Aventis Biosimilar Sales, Revenue, Price and Gross Margin (2012-2017)
  6.6.4 Main Business/Business Overview
6.7 Johnson & Johnson
  6.7.2 Biosimilar Product Category, Application and Specification
    6.7.2.1 Product A
    6.7.2.2 Product B
  6.7.3 Johnson & Johnson Biosimilar Sales, Revenue, Price and Gross Margin (2012-2017)
  6.7.4 Main Business/Business Overview
6.8 Novo Nordisk
  6.8.2 Biosimilar Product Category, Application and Specification
    6.8.2.1 Product A
    6.8.2.2 Product B
  6.8.3 Novo Nordisk Biosimilar Sales, Revenue, Price and Gross Margin (2012-2017)
  6.8.4 Main Business/Business Overview
6.9 Merck
  6.9.2 Biosimilar Product Category, Application and Specification
    6.9.2.1 Product A
    6.9.2.2 Product B
  6.9.3 Merck Biosimilar Sales, Revenue, Price and Gross Margin (2012-2017)
  6.9.4 Main Business/Business Overview

7 BIOSIMILAR MANUFACTURING COST ANALYSIS

7.1 Biosimilar Key Raw Materials Analysis
  7.1.1 Key Raw Materials
  7.1.2 Price Trend of Key Raw Materials
  7.1.3 Key Suppliers of Raw Materials
  7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
  7.2.1 Raw Materials
  7.2.2 Labor Cost
  7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Biosimilar

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 Biosimilar Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Biosimilar Major Manufacturers in 2016
8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

9.1 Marketing Channel
  9.1.1 Direct Marketing
  9.1.2 Indirect Marketing
  9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
  9.2.1 Pricing Strategy
  9.2.2 Brand Strategy
  9.2.3 Target Client
9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk
  10.1.1 Substitutes Threat
  10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 UNITED STATES BIOSIMILAR MARKET SIZE (VALUE AND VOLUME) FORECAST (2017-2022)

11.1 United States Biosimilar Sales Volume, Revenue Forecast (2017-2022)
11.2 United States Biosimilar Sales Volume Forecast by Type (2017-2022)
11.3 United States Biosimilar Sales Volume Forecast by Application (2017-2022)
11.4 United States Biosimilar Sales Volume Forecast by Region (2017-2022)

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

13.1 Methodology/Research Approach
  13.1.1 Research Programs/Design
  13.1.2 Market Size Estimation
  13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
  13.2.1 Secondary Sources
  13.2.2 Primary Sources
13.3 Disclaimer

The report requires updating with new data and is sent in 2-3 business days after order is placed.

List Of Tables

LIST OF TABLES AND FIGURES

Figure Product Picture of Biosimilar
Figure United States Biosimilar Market Size (K Units) by Type (2012-2022)
Figure United States Biosimilar Sales Volume Market Share by Type (Product Category) in 2016
Figure Antibody Product Picture
Figure Hormone Product Picture
Figure Growth Factors Product Picture
Figure Other Product Picture
Figure United States Biosimilar Market Size (K Units) by Application (2012-2022)
Figure United States Sales Market Share of Biosimilar by Application in 2016
Figure Tumor Examples
Table Key Downstream Customer in Tumor
Figure Diabetes Examples
Table Key Downstream Customer in Diabetes
Figure Cardiovascular Examples
Table Key Downstream Customer in Cardiovascular
Figure Hemophilia Examples
Table Key Downstream Customer in Hemophilia
Figure Other Examples
Table Key Downstream Customer in Other
Figure United States Biosimilar Market Size (Million USD) by Region (2012-2022)
Figure The West Biosimilar Revenue (Million USD) and Growth Rate (2012-2022)
Figure Southwest Biosimilar Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Middle Atlantic Biosimilar Revenue (Million USD) and Growth Rate (2012-2022)
Figure New England Biosimilar Revenue (Million USD) and Growth Rate (2012-2022)
Figure The South of US Biosimilar Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Midwest Biosimilar Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Biosimilar Sales (K Units) and Growth Rate (2012-2022)
Figure United States Biosimilar Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Biosimilar Market Major Players Product Sales Volume (K Units) (2012-2017)
Table United States Biosimilar Sales (K Units) of Key Players/Suppliers (2012-2017)
Table United States Biosimilar Sales Share by Players/Suppliers (2012-2017)
Figure 2016 United States Biosimilar Sales Share by Players/Suppliers
Figure 2017 United States Biosimilar Sales Share by Players/Suppliers
Figure United States Biosimilar Market Major Players Product Revenue (Million USD) (2012-2017)
Table United States Biosimilar Revenue (Million USD) by Players/Suppliers (2012-2017)
Table United States Biosimilar Revenue Share by Players/Suppliers (2012-2017)
Figure 2016 United States Biosimilar Revenue Share by Players/Suppliers
Figure 2017 United States Biosimilar Revenue Share by Players/Suppliers
Table United States Market Biosimilar Average Price (USD/Unit) of Key Players/Suppliers (2012-2017)
Figure United States Market Biosimilar Average Price (USD/Unit) of Key Players/Suppliers in 2016
Figure United States Biosimilar Market Share of Top 3 Players/Suppliers
Figure United States Biosimilar Market Share of Top 5 Players/Suppliers
Table United States Players/Suppliers Biosimilar Manufacturing Base Distribution and Sales Area
Table United States Players/Suppliers Biosimilar Product Category
Table United States Biosimilar Sales (K Units) by Region (2012-2017)
Table United States Biosimilar Sales Share by Region (2012-2017)
Figure United States Biosimilar Sales Share by Region (2012-2017)
Figure United States Biosimilar Sales Market Share by Region in 2016
Table United States Biosimilar Revenue (Million USD) and Market Share by Region (2012-2017)
Table United States Biosimilar Revenue Share by Region (2012-2017)
Figure United States Biosimilar Revenue Market Share by Region (2012-2017)
Figure United States Biosimilar Revenue Market Share by Region in 2016
Table United States Biosimilar Price (USD/Unit) by Region (2012-2017)
Table United States Biosimilar Sales (K Units) by Type (2012-2017)
Table United States Biosimilar Sales Share by Type (2012-2017)
Figure United States Biosimilar Sales Share by Type (2012-2017)
Figure United States Biosimilar Sales Market Share by Type in 2016
Table United States Biosimilar Revenue (Million USD) and Market Share by Type (2012-2017)
Table United States Biosimilar Revenue Share by Type (2012-2017)
Figure Revenue Market Share of Biosimilar by Type (2012-2017)
Figure Revenue Market Share of Biosimilar by Type in 2016
Table United States Biosimilar Price (USD/Unit) by Types (2012-2017)
Figure United States Biosimilar Sales Growth Rate by Type (2012-2017)
Table United States Biosimilar Sales (K Units) by Application (2012-2017)
Table United States Biosimilar Sales Market Share by Application (2012-2017)
Figure United States Biosimilar Sales Market Share by Application (2012-2017)
Figure United States Biosimilar Sales Market Share by Application in 2016
Table United States Biosimilar Sales Growth Rate by Application (2012-2017)
Figure United States Biosimilar Sales Growth Rate by Application (2012-2017)
Table Pfizer Basic Information List
Table Pfizer Biosimilar Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Pfizer Biosimilar Sales Growth Rate (2012-2017)
Figure Pfizer Biosimilar Sales Market Share in United States (2012-2017)
Figure Pfizer Biosimilar Revenue Market Share in United States (2012-2017)
Table Roche Basic Information List
Table Roche Biosimilar Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Roche Biosimilar Sales Growth Rate (2012-2017)
Figure Roche Biosimilar Sales Market Share in United States (2012-2017)
Figure Roche Biosimilar Revenue Market Share in United States (2012-2017)
Table Eli Lilly Basic Information List
Table Eli Lilly Biosimilar Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Eli Lilly Biosimilar Sales Growth Rate (2012-2017)
Figure Eli Lilly Biosimilar Sales Market Share in United States (2012-2017)
Figure Eli Lilly Biosimilar Revenue Market Share in United States (2012-2017)
Table Bayer Basic Information List
Table Bayer Biosimilar Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Bayer Biosimilar Sales Growth Rate (2012-2017)
Figure Bayer Biosimilar Sales Market Share in United States (2012-2017)
Figure Bayer Biosimilar Revenue Market Share in United States (2012-2017)
Table Amgen Basic Information List
Table Amgen Biosimilar Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Amgen Biosimilar Sales Growth Rate (2012-2017)
Figure Amgen Biosimilar Sales Market Share in United States (2012-2017)
Figure Amgen Biosimilar Revenue Market Share in United States (2012-2017)
Table Sanofi-Aventis Basic Information List
Table Sanofi-Aventis Biosimilar Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Sanofi-Aventis Biosimilar Sales Growth Rate (2012-2017)
Figure Sanofi-Aventis Biosimilar Sales Market Share in United States (2012-2017)
Figure Sanofi-Aventis Biosimilar Revenue Market Share in United States (2012-2017)
Table Johnson & Johnson Basic Information List
Table Johnson & Johnson Biosimilar Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Johnson & Johnson Biosimilar Sales Growth Rate (2012-2017)
Figure Johnson & Johnson Biosimilar Sales Market Share in United States (2012-2017)
Figure Johnson & Johnson Biosimilar Revenue Market Share in United States (2012-2017)
Table Novo Nordisk Basic Information List
Table Novo Nordisk Biosimilar Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Novo Nordisk Biosimilar Sales Growth Rate (2012-2017)
Figure Novo Nordisk Biosimilar Sales Market Share in United States (2012-2017)
Figure Novo Nordisk Biosimilar Revenue Market Share in United States (2012-2017)
Table Merck Basic Information List
Table Merck Biosimilar Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Merck Biosimilar Sales Growth Rate (2012-2017)
Figure Merck Biosimilar Sales Market Share in United States (2012-2017)
Figure Merck Biosimilar Revenue Market Share in United States (2012-2017)
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Biosimilar
Figure Manufacturing Process Analysis of Biosimilar
Figure Biosimilar Industrial Chain Analysis
Table Raw Materials Sources of Biosimilar Major Players/Suppliers in 2016
Table Major Buyers of Biosimilar
Table Distributors/Traders List
Figure United States Biosimilar Sales Volume (K Units) and Growth Rate Forecast (2017-2022)
Figure United States Biosimilar Revenue (Million USD) and Growth Rate Forecast (2017-2022)
Figure United States Biosimilar Price (USD/Unit) Trend Forecast (2017-2022)
Table United States Biosimilar Sales Volume (K Units) Forecast by Type (2017-2022)
Figure United States Biosimilar Sales Volume (K Units) Forecast by Type (2017-2022)
Figure United States Biosimilar Sales Volume (K Units) Forecast by Type in 2022
Table United States Biosimilar Sales Volume (K Units) Forecast by Application (2017-2022)
Figure United States Biosimilar Sales Volume (K Units) Forecast by Application (2017-2022)
Figure United States Biosimilar Sales Volume (K Units) Forecast by Application in 2022
Table United States Biosimilar Sales Volume (K Units) Forecast by Region (2017-2022)
Table United States Biosimilar Sales Volume Share Forecast by Region (2017-2022)
Figure United States Biosimilar Sales Volume Share Forecast by Region (2017-2022)
Figure United States Biosimilar Sales Volume Share Forecast by Region in 2022
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources